B
Bull
Bull · 25%NXGL
$6.00
Szenariopreis
$0.358
-0.001 (-0.22%)Zum Schluss
Loading chart…
- High
- 0.366
- Open
- 0.344
- VWAP
- 0.36
- Vol
- 171.69K
- Mkt Cap
- 13.55M
- Low
- 0.343
- Amount
- 61.08K
- EV/EBITDA, TTM
- -0.70
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.
AI analysis of Nexgel Inc (NXGL)
holdNexgel Inc is not a good buy right now due to its significant financial challenges and recent downgrades by analysts. The stock is currently priced at $0.35, with a year-to-date change of -80.55%, indicating severe underperformance. Additionally, the company reported a net income loss of $3.635 million in Q2 2026, which raises concerns about its financial health.
Bewertungskennzahlen
The current forward P/E ratio for Nexgel Inc (NXGL) is 1.38, compared to its 5-year average forward P/E of -12.58.
Alphio AI Price Scenarios for NXGL
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
9.505-15seekingalphaNEXGEL Reports Q1 Earnings Miss
5.005-13NewsfilterNEXGEL Appoints New VP of Sales to Drive BIONX Surgical Division Growth
- 9.505-12Newsfilter
NEXGEL to Report Q1 2026 Financial Results on May 15
- 5.004-27Newsfilter
NEXGEL Appoints New CFO to Integrate Acquisition and Accelerate Growth
5.004-27moomooNEXGEL NAMES IAN BLACKMAN AS CFO
NXGL FAQ — answered by Alphio AI
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Nexgel Inc is not a good buy right now due to its significant financial challenges and recent downgrades by analysts. The stock is currently priced at $0.35, with a year-to-date change of -80.55%, indicating severe underperformance. Additionally, the company reported a net income loss of $3.635 million in Q2 2026, which raises concerns about its financial health.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.